Takeda Ventures Investor

TVI's mission is to identify, help create and support the development of therapeutic innovation that aligns with Takeda’s own strategic imperatives. They do this by investing in technology and product concepts, and highly effective teams that can turn ideas into reality. Their primary focus is on medium to longer term returns in the form of product and technology successes for their portfolio companies and capital gains for the financial institutions they work with. As a Pharma strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts from preclinical through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. TVI is based in Palo Alto, California and is actively seeking global investment opportunities. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on cardiometabolic, central nervous system, chronic inflammatory and immune modulation, and oncology therapeutic domains. Their focus also includes new platforms for drug target and biomarker identification, regenerative medicines, innovative vaccines technologies and delivery systems for novel protein and peptide therapeutics. TVI currently does not invest in diagnostics platforms, medical technology and devices or anti-infective products.
Technology: N/A
Industry: Precision Medicine
Headquarters: Palo Alto, California, United States
Founded Date: 2001
Employees Number: 1-10
Funding Status: undisclosed
Investor Type: Corporate Venture Capital
Investment Stage: Early Stage Venture, Late Stage Venture
Number Of Exits: 6

Visit Website
Register and Claim Ownership